Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Regeneron Pharmaceuticals Reports Positive Phase 2 Results for Antithrombotic Antibodies REGN7508 and REGN9933 Targeting Factor XI Quiver Quantitative, Inc. - Thu Dec 19, 4:20PM CST

Regeneron reveals positive Phase 2 results for two Factor XI monoclonal antibodies, targeting thrombosis with favorable safety profiles.Quiver AI SummaryRegeneron Pharmaceuticals has announced positive...

REGN : 701.85 (-0.90%)
Bull and bear by Nosheep via Pixabay
Should You Scoop Up This 'Strong Buy' Biotech Before December 23? Barchart - Thu Dec 19, 7:00AM CST

Does this top-rated biotech stock deserve a spot in investors' portfolios before its Russell 2000 inclusion?

UPB : 16.21 (-2.41%)
REGN : 701.85 (-0.90%)
AMGN : 263.38 (+0.84%)
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results GlobeNewswire - Thu Dec 19, 6:00AM CST

REGN : 701.85 (-0.90%)
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Dec 17, 3:05PM CST

REGN : 701.85 (-0.90%)
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion GlobeNewswire - Tue Dec 17, 6:00AM CST

REGN : 701.85 (-0.90%)
Regeneron Pharmaceuticals, Inc. Achieves Continued Recognition in Dow Jones Sustainability Indices for 2024 Quiver Quantitative, Inc. - Tue Dec 17, 1:56AM CST

Regeneron Pharmaceuticals announced its sixth inclusion in the Dow Jones Sustainability World Index, reflecting strong corporate responsibility and governance.Quiver AI SummaryRegeneron Pharmaceuticals...

REGN : 701.85 (-0.90%)
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year GlobeNewswire - Mon Dec 16, 3:30PM CST

REGN : 701.85 (-0.90%)
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases Zacks Investment Research - Mon Dec 16, 1:44PM CST

Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).The regulatory body approved Vabysmo PFS for use in the treatment...

GILD : 92.57 (+1.62%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
BMY : 57.33 (+1.83%)
Regeneron Down 15.5% Year to Date: How to Play the Stock?
Regeneron Down 15.5% Year to Date: How to Play the Stock? Zacks Investment Research - Fri Dec 13, 9:12AM CST

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 4.9100 (-0.41%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
SNY : 47.71 (+0.44%)
Regeneron Pharmaceuticals Reports Promising Clinical Results for Odronextamab in Treating Various Forms of B-Cell Non-Hodgkin Lymphoma at ASH 2024 Quiver Quantitative, Inc. - Tue Dec 10, 2:58AM CST

Odronextamab shows promise in treating various B-cell lymphomas, with notable efficacy and safety results across multiple trials.Quiver AI SummaryRegeneron Pharmaceuticals announced promising results from...

REGN : 701.85 (-0.90%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot